This is the first report studied on the predictive significance of plasmatic levels of HSP90α at diagnosis in advanced lung cancer patients treated with PD1/PD-L1 inhibitors plus chemotherapy. This evidence concerns the gene HSP90AA1 and lung carcinoma.